CRBP — Corbus Pharmaceuticals Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1595097 ·
Last close
$3.01
Market Cap
$62.03M
52W High
$12.88
52W Low
$2.81
ADV30
1,090,628
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -38,824,000 | -37,754,000 | 122,902,000 | 30,246,000 | 38,144,000 |
| Jun 2026 | 0 | — | -36,190,000 | -35,037,000 | 126,988,000 | 23,370,000 | 24,748,000 |
| Mar 2026 | 0 | — | -24,304,000 | -22,969,000 | 144,480,000 | 25,661,000 | 18,138,000 |
| Dec 2025 | 0 | — | -21,966,000 | -20,555,000 | 168,195,000 | 28,492,000 | 20,692,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-92,357,000
Investing CF
$-6,868,000
Financing CF
$95,979,000
CapEx
$-27,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.10
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-651,190,000
Inventory
—
Receivables
—
ST Investments
$85,091,000
EBIT TTM
$-119,873,000
Pretax Income TTM
$-116,315,000
Interest Exp TTM
$0
Analysts
9
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -85,310,000 | -78,537,000 | 168,195,000 | 20,692,000 | 147,503,000 | -64,491,000 |
| Dec 2024 | 0 | -48,721,000 | -40,209,000 | 155,879,000 | 13,451,000 | 142,428,000 | -41,794,000 |
| Dec 2023 | 0 | -45,078,000 | -44,604,000 | 28,272,000 | 35,177,000 | -6,905,000 | -36,100,000 |
| Dec 2022 | 0 | -34,835,445 | -42,346,903 | 66,311,940 | 33,321,923 | 32,990,017 | -37,544,435 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-101,903,000
OpCashFlow TTM
—
Assets (Latest)
$126,988,000
Forward EPS
$-5.19
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $4.00 · spot: $2.74 · call volume: 61 · put volume: 106
Expected Move to 2026-12-18:
±$2.32
(84.52%) —
implied range
$0.42 –
$5.06
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc. | $61.28M | $1.43 | — |
| FBIO | Fortress Biotech, Inc. | $60.70M | $1.82 | — |
| KZIA | KAZIA THERAPEUTICS LTD | $60.68M | $5.31 | — |
| LFVN | Lifevantage Corp | $60.62M | $4.78 | — |
| RANI | Rani Therapeutics Holdings, Inc. | $64.61M | $0.56 | — |
News headlines (Yahoo Finance, 1h cache)
Corbus Pharmaceuticals Starts Phase 3 Cancer Study, Weighs Next Steps for Obesity Drug
2026-11-18 11:12 · Yahoo
Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
2026-11-16 13:00 · Yahoo
Corbus Pharmaceuticals: Q3 Earnings Snapshot
2026-11-10 13:16 · Yahoo
Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update
2026-11-10 13:00 · Yahoo
Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data
2026-11-09 23:14 · Yahoo
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November
2026-11-05 13:00 · Yahoo
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
2026-10-22 12:00 · Yahoo
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
2026-09-29 12:00 · Yahoo
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
2026-09-15 08:02 · Yahoo
Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data
2026-09-14 13:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.